semaglutide eye damage Associated With Optic Neuropathy That Can Lead to Blindness, Mass and Ear Researchers Report Semaglutide Tied to Increased Risk
Description
Obtain informed consent
These drugs are administered as a weekly injection, given subcutaneously, under the skin
Wegovy contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines
Additionally, it inhibited a-glucosidase activity, further supporting its potential as a therapeutic agent for diabetes management []
